Cameco Corporation

New York Stock Exchange
Back to all articles
Somewhat Bullish +35

Engle Capital Management L.P. Has $3.35 Million Stake in Cameco ...

📉 Engle Capital Management L.P. reduced its CCJ stake by 33.3% in Q1, selling 15,397 shares to hold a remaining position valued at $3.35 million.

🏦 Sterling Capital Management LLC and Nisa Investment Advisors LLC initiated new stakes in Cameco worth approximately $30,000 and $25,000 respectively during the first quarter.

📈 Brown Lisle Cummings Inc. grew its CCJ holdings by 3,200% in Q1, now owning 297 shares valued at $32,000 after buying an additional 288 shares.

📊 Founders Capital Management and McGuire Capital Advisors Inc. acquired new positions in Cameco during the fourth quarter valued at roughly $27,000 and $28,000.

🏛️ Institutional ownership of CCJ stands at 70.21%, indicating significant hedge fund and institutional investor interest in the uranium producer.

💰 Cameco Corporation has a market capitalization of $38.89 billion with a PE ratio of 82.68 and a debt-to-equity ratio of 0.14.

📉 Barclays lowered its price objective for CCJ from $108.00 to $104.00 and set an 'equal weight' rating in a July 15th report.

🔼 Scotiabank reissued an 'outperform' rating with a $175.00 price objective, while Bank of America maintained a 'buy' rating but reduced its target to $140.

📈 Truist Financial initiated coverage on CCJ with a 'buy' rating and a $129.00 target price in a July 13th research report.

🎯 The stock currently has a consensus rating of 'Moderate Buy' with a consensus price target of $146.18 based on MarketBeat data.

📉 CCJ opened at $89.29, trading between a 52-week low of $68.96 and a high of $135.24 with a beta of 1.02.

⚙️ The company operates uranium mining and processing properties in Canada and the United States, producing yellowcake for nuclear reactors.

Bullish Signals
  • Institutional investors like Brown Lisle Cummings Inc. significantly increased their holdings by 3,200% in Q1, signaling strong confidence in the company's prospects.
  • Multiple analysts maintain 'buy' or 'outperform' ratings, including Scotiabank with a high $175 price target and Truist Financial initiating coverage with a buy rating.
  • The company maintains a very strong balance sheet with a debt-to-equity ratio of 0.14 and a current ratio of 3.08, indicating low financial risk.
  • New institutional capital is entering the stock, with several firms like Founders Capital Management and McGuire Capital Advisors acquiring new positions in Q4.
Risk Factors
  • Engle Capital Management L.P. reduced its stake by 33.3% in Q1, selling over 15,000 shares which may indicate a lack of near-term upside from this specific investor.
  • Barclays lowered its price objective to $104 and downgraded the sentiment to 'equal weight', suggesting potential downside or neutral outlook compared to previous targets.
  • Bank of America reduced its price target from $143.00 to $140.00, indicating a slight adjustment in valuation expectations despite maintaining a buy rating.
  • The stock trades below its 200-day simple moving average of $110.48 and is currently at $89.29, suggesting it may be underperforming recent technical trends.
Full Analysis
Engle Capital Management L.P. reduced its stake in Cameco Corporation (NYSE: CCJ) by 33.3% during the first quarter, selling 15,397 shares to hold a remaining position of 30,833 shares valued at $3.35 million. This reduction brings Cameco to represent 1.1% of Engle's portfolio, marking it as the firm's 21st largest holding. The filing indicates a shift in institutional positioning for the uranium producer amidst broader market activity. Several other institutional investors have adjusted their stakes in CCJ during recent quarters. Sterling Capital Management LLC initiated a new stake valued at approximately $30,000, while Nisa Investment Advisors LLC and Founders Capital Management also acquired new positions worth roughly $25,000 and $27,000 respectively. Brown Lisle Cummings Inc. significantly grew its holdings by 3,200%, now owning 297 shares valued at $32,000 after adding to its position in the last quarter. Analyst sentiment remains mixed with a consensus rating of 'Moderate Buy' and a price target of $146.18. Recent reports include Barclays lowering its price objective to $104 with an 'equal weight' rating, while Bank of America maintained a 'buy' rating but reduced its target to $140. Conversely, Scotiabank issued an 'outperform' rating with a higher $175 price target, and Truist Financial initiated coverage with a 'buy' rating at $129. Cameco Corporation operates as a leading producer of uranium and supplier to the global nuclear power industry, headquartered in Saskatoon, Saskatchewan. The company is engaged in exploration, mining, milling, and sale of uranium concentrate used for nuclear reactors, operating primarily in Canada and the United States. Financial metrics show a market capitalization of $38.89 billion with a PE ratio of 82.68 and a debt-to-equity ratio of 0.14.